4,0
21 dic 2021
Dipendente attuale, meno di un anno
Fremont, CA
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Growing company, well compensated, generally good collaboration across regions
Svantaggi
Typical growing pains of a biotech evolving into midsize pharma, nothing particularly negative though